دورية أكاديمية
أعرض في EDS

Lipid Metabolism Regulators Are the Possible Determinant for Characteristics of Myopic Human Scleral Stroma Fibroblasts (HSSFs).

التفاصيل البيبلوغرافية
العنوان: Lipid Metabolism Regulators Are the Possible Determinant for Characteristics of Myopic Human Scleral Stroma Fibroblasts (HSSFs).
المؤلفون: Ohguro H; Department of Ophthalmology, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Hokkaido, Japan., Umetsu A; Department of Ophthalmology, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Hokkaido, Japan., Sato T; Department of Cardiovascular, Renal and Metabolic Medicine, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Hokkaido, Japan.; Department of Cellular Physiology and Signal Transduction, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Hokkaido, Japan., Furuhashi M; Department of Cardiovascular, Renal and Metabolic Medicine, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Hokkaido, Japan., Watanabe M; Department of Ophthalmology, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Hokkaido, Japan.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2023 Dec 29; Vol. 25 (1). Date of Electronic Publication: 2023 Dec 29.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: Lipid Metabolism*/genetics , Myopia*, Humans ; Sclera ; Fibroblasts ; Computational Biology ; Fatty Acids
مستخلص: The purpose of the current investigation was to elucidate what kinds of responsible mechanisms induce elongation of the sclera in myopic eyes. To do this, two-dimensional (2D) cultures of human scleral stromal fibroblasts (HSSFs) obtained from eyes with two different axial length (AL) groups, <26 mm (low AL group, n = 2) and >27 mm (high AL group, n = 3), were subjected to (1) measurements of Seahorse mitochondrial and glycolytic indices to evaluate biological aspects and (2) analysis by RNA sequencing. Extracellular flux analysis revealed that metabolic indices related to mitochondrial and glycolytic functions were higher in the low AL group than in the high AL group, suggesting that metabolic activities of HSSF cells are different depending the degree of AL. Based upon RNA sequencing of these low and high AL groups, the bioinformatic analyses using gene ontology (GO) enrichment analysis and ingenuity pathway analysis (IPA) of differentially expressed genes (DEGs) identified that sterol regulatory element-binding transcription factor 2 (SREBF2) is both a possible upstream regulator and a causal network regulator. Furthermore, SREBF1, insulin-induced gene 1 (INSIG1), and insulin-like growth factor 1 (IGF1) were detected as upstream regulators, and protein tyrosine phosphatase receptor type O (PTPRO) was detected as a causal network regulator. Since those possible regulators were all pivotally involved in lipid metabolisms including fatty acid (FA), triglyceride (TG) and cholesterol (Chol) biosynthesis, the findings reported here indicate that FA, TG and Chol biosynthesis regulation may be responsible mechanisms inducing AL elongation via HSSF.
References: Prog Mol Biol Transl Sci. 2015;134:241-8. (PMID: 26310158)
Mol Vis. 2012;18:634-44. (PMID: 22509095)
Metabolism. 2012 Aug;61(8):1118-28. (PMID: 22386934)
Trans Am Ophthalmol Soc. 1977;75:67-86. (PMID: 613534)
Metab Pediatr Syst Ophthalmol. 1983;7(4):183-8. (PMID: 6678372)
Int J Mol Sci. 2023 Jan 01;24(1):. (PMID: 36614215)
Cells. 2022 Jan 16;11(2):. (PMID: 35053416)
Endocrinology. 2019 Jan 1;160(1):20-35. (PMID: 30388216)
Invest Ophthalmol Vis Sci. 2023 Mar 1;64(3):7. (PMID: 36867130)
Development. 2022 Jul 15;149(14):. (PMID: 35833708)
Int J Mol Sci. 2023 Oct 04;24(19):. (PMID: 37834331)
Sci Rep. 2023 Apr 3;13(1):5386. (PMID: 37012316)
Endocr Connect. 2012 Jun 21;1(1):31-6. (PMID: 23781301)
Mol Genet Genomics. 2023 Sep;298(5):1059-1071. (PMID: 37277661)
Sci Rep. 2021 Apr 26;11(1):9002. (PMID: 33903711)
Heliyon. 2023 Oct 05;9(10):e20713. (PMID: 37867843)
Exp Eye Res. 2018 Nov;176:235-242. (PMID: 30193807)
Exp Eye Res. 2006 Feb;82(2):185-200. (PMID: 16202407)
PLoS One. 2022 Jul 21;17(7):e0271809. (PMID: 35862416)
Prog Retin Eye Res. 2018 Jan;62:134-149. (PMID: 28951126)
Compr Physiol. 2014 Jan;4(1):177-97. (PMID: 24692138)
Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2050-8. (PMID: 10892842)
Mol Cell. 1998 Oct;2(4):505-14. (PMID: 9809072)
Bioinformatics. 2014 Feb 15;30(4):523-30. (PMID: 24336805)
PeerJ. 2021 Nov 19;9:e12452. (PMID: 34820188)
Cancer Commun (Lond). 2022 Sep;42(9):848-867. (PMID: 35904817)
JAMA. 1994 May 4;271(17):1323-7. (PMID: 8158816)
Cell. 1993 Oct 8;75(1):187-97. (PMID: 8402897)
J Invest Dermatol. 2008 May;128(5):1286-93. (PMID: 17989724)
Int J Mol Sci. 2018 Oct 26;19(11):. (PMID: 30373107)
Exp Eye Res. 2015 Apr;133:100-11. (PMID: 25819458)
Am J Hum Genet. 1998 Nov;63(5):1419-24. (PMID: 9792869)
Clin Ophthalmol. 2013;7:2057-62. (PMID: 24204106)
Invest Ophthalmol Vis Sci. 2017 Apr 1;58(4):1971-1981. (PMID: 28384717)
EMBO J. 2011 Apr 6;30(7):1357-75. (PMID: 21407177)
Exp Eye Res. 1984 Nov;39(5):533-42. (PMID: 6519194)
J Clin Invest. 2002 May;109(9):1125-31. (PMID: 11994399)
Eye (Lond). 2022 May;36(5):921-929. (PMID: 34645966)
Mol Vis. 2011;17:1436-48. (PMID: 21655358)
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4476-9. (PMID: 20435602)
N Engl J Med. 2000 Oct 26;343(17):1236-48. (PMID: 11071676)
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12753-8. (PMID: 12242332)
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3484-92. (PMID: 16186323)
Prog Retin Eye Res. 2003 May;22(3):307-38. (PMID: 12852489)
Curr Issues Mol Biol. 2021 Oct 22;43(3):1715-1725. (PMID: 34698138)
PLoS One. 2015 Jun 15;10(6):e0129707. (PMID: 26076017)
Exp Eye Res. 2022 Sep;222:109184. (PMID: 35820467)
Cells. 2023 Feb 27;12(5):. (PMID: 36899895)
Sci Rep. 2020 Nov 20;10(1):20292. (PMID: 33219246)
Ophthalmology. 2014 Sep;121(9):1798-809. (PMID: 24813630)
Exp Eye Res. 2012 Jun;99:1-16. (PMID: 22695224)
Br J Ophthalmol. 2018 Jul;102(7):855-862. (PMID: 29699985)
Cell. 1996 Nov 1;87(3):415-26. (PMID: 8898195)
Acta Ophthalmol (Copenh). 1971;49(6):873-86. (PMID: 5172264)
J Clin Invest. 1997 Mar 1;99(5):846-54. (PMID: 9062341)
Nat Methods. 2015 Apr;12(4):357-60. (PMID: 25751142)
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):13. (PMID: 32503053)
J Biol Chem. 2003 May 9;278(19):16587-94. (PMID: 12606541)
Prog Retin Eye Res. 2020 Jan;74:100773. (PMID: 31412277)
J Clin Invest. 1998 Jun 1;101(11):2331-9. (PMID: 9616204)
Stem Cell Res Ther. 2021 May 29;12(1):304. (PMID: 34051850)
J Clin Invest. 2009 May;119(5):1201-15. (PMID: 19363290)
Nat Commun. 2021 May 21;12(1):3005. (PMID: 34021134)
Invest Ophthalmol Vis Sci. 2021 Apr 28;62(5):5. (PMID: 33909033)
Mol Cell. 1997 Dec;1(1):47-57. (PMID: 9659902)
Cell. 2002 Aug 23;110(4):489-500. (PMID: 12202038)
Mol Vis. 2013 May 21;19:1074-81. (PMID: 23734076)
Mol Cell Biol. 1993 Aug;13(8):4753-9. (PMID: 8336713)
فهرسة مساهمة: Keywords: RNA sequencing; cholesterol biosynthesis; human scleral stroma fibroblasts (HSSFs); insulin-induced gene 1 (INSIG1); insulin-like growth factor 1 (IGF1); myopia; protein tyrosine phosphatase receptor type O (PTPRO); sterol regulatory element-binding transcription factor (SREBF)
المشرفين على المادة: 0 (Fatty Acids)
تواريخ الأحداث: Date Created: 20240111 Date Completed: 20240112 Latest Revision: 20240113
رمز التحديث: 20240113
مُعرف محوري في PubMed: PMC10778967
DOI: 10.3390/ijms25010501
PMID: 38203671
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25010501